# Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT04987307** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 221 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Efavaleukin alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04987307
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-31
- **Primary completion:** 2024-10-22
- **Final completion:** 2024-10-22
- **Target enrollment:** 221 (ACTUAL)
- **Why stopped:** The study was terminated due to meeting a prespecified futility rule and not related to any safety concerns.
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04987307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04987307, "Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04987307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*